Form 4: KalVista Director Granted 30,000 Stock Options

KalVista Pharmaceuticals Director Brian JG Pereira was granted 30,000 stock options with an exercise price of $12.05, vesting over 12 months.

Summary

• Director Brian JG Pereira of KalVista Pharmaceuticals, Inc. (KALV) was granted 30,000 stock options.
• The options have an exercise price of $12.05 per share.
• The earliest transaction date for this grant is October 1, 2025.
• The options vest over a 12-month period, with 1/12th vesting on November 1, 2025, and subsequent 1/12th portions vesting monthly thereafter.
• Vesting is contingent upon continued service through each vesting date.
• The expiration date for these stock options is September 30, 2035.
• Following this transaction, Brian JG Pereira beneficially owns 30,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as it reflects standard director compensation, aligning interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice to attract and retain experienced board members in the biotechnology sector.

Negatives

• The future exercise of these options could lead to minor share dilution, although this is a common aspect of equity compensation plans.

Risks

• The vesting of the stock options is subject to Brian JG Pereira's continued service through each vesting date, meaning unvested options could be forfeited if service ceases.

Future Outlook

The vesting schedule indicates a commitment for the director's continued service to the company over the next 12 months, with monthly vesting increments beginning November 1, 2025.

Industry Context

This stock option grant is a common form of equity compensation for directors in the biotechnology and pharmaceutical industries, designed to align leadership incentives with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is consistent with common compensation practices observed across the biotechnology sector, where equity incentives are frequently used to attract and retain talent and align interests with company performance.
• Specific comparable companies, projects, or results are not detailed within this filing to provide a direct benchmark, but the structure of the grant is typical for director compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for minor future dilution upon exercise of options, but also benefits from enhanced director alignment with long-term company performance.
• Employees: No direct impact mentioned, but reflects standard compensation practices for leadership.

Next Steps

• The stock options will begin vesting on November 1, 2025, with subsequent monthly vesting increments.
• The director's continued service will be required for the options to fully vest over the 12-month period.

Key Dates

Keywords

KalVista Pharmaceuticals, KALV, Stock Options, Director Compensation, Insider Transaction, Equity Grant, Form 4, Biotechnology